Stay updated with breaking news from Veracyte Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) Director Karin Eastham sold 2,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $20.97, for a total transaction of $52,425.00. Following the completion of the transaction, the director now directly owns 33,125 shares of […]
Veracyte, Inc. announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings,...
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. Equity markets surged at the beginning of 2024 in anticipation of the US economy entering a “goldilocks” scenario – a soft landing combined with decreasing inflation, potentially leading to […]
The Medical Instruments industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on. This industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas.
Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target […]